---
title: Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody
  Treatment in Large B-Cell Lymphoma
date: '2024-04-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38657242/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240425181115&v=2.18.0.post9+e462414
source: Blood
description: In this retrospective study, CAR T-cells remained effective in relapsed/refractory
  LBCL patients after prior exposure to bispecific antibodies (BsAbs) targeting different
  antigens. These results are relevant to clinical practice, particularly given the
  increasing use of BsAbs in earlier treatment ...
disable_comments: true
---
In this retrospective study, CAR T-cells remained effective in relapsed/refractory LBCL patients after prior exposure to bispecific antibodies (BsAbs) targeting different antigens. These results are relevant to clinical practice, particularly given the increasing use of BsAbs in earlier treatment ...